Abstract
Recent studies suggest that nuclear factor κB-inducing kinase (NIK) is suppressed through constitutive proteasome-mediated degradation regulated by TRAF2, TRAF3 and cIAP1 or cIAP2. Here we demonstrated that the degradation of NIK occurs upon assembly of a regulatory complex through TRAF3 recruitment of NIK and TRAF2 recruitment of cIAP1 and cIAP2. In contrast to TRAF2 and TRAF3, cIAP1 and cIAP2 seem to play redundant roles in the degradation of NIK, as inhibition of both cIAPs was required for noncanonical NF-κB activation and increased survival and proliferation of primary B lymphocytes. Furthermore, the lethality of TRAF3 deficiency in mice could be rescued by a single NIK gene, highlighting the importance of tightly regulated NIK.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baeuerle, P.A. & Baltimore, D. NF-κB: ten years after. Cell 87, 13–20 (1996).
Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3, 1285–1289 (1997).
Kopp, E.B. & Ghosh, S. NF-κB and rel proteins in innate immunity. Adv. Immunol. 58, 1–27 (1995).
Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280–288 (2004).
Zandi, E. & Karin, M. Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol. Cell. Biol. 19, 4547–4551 (1999).
Coope, H.J. et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 21, 5375–5385 (2002).
Claudio, E., Brown, K., Park, S., Wang, H. & Siebenlist, U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat. Immunol. 3, 958–965 (2002).
Dejardin, E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72, 1161–1179 (2006).
Matsushima, A. et al. Essential role of nuclear factor (NF)-κB-inducing kinase and inhibitor of κB (IκB) kinase α in NF-κB activation through lymphotoxin β receptor, but not through tumor necrosis factor receptor I. J. Exp. Med. 193, 631–636 (2001).
Shinkura, R. et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding NF-κB-inducing kinase. Nat. Genet. 22, 74–77 (1999).
Yin, L. et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 291, 2162–2165 (2001).
Liao, G., Zhang, M., Harhaj, E.W. & Sun, S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279, 26243–26250 (2004).
He, J.Q. et al. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J. Exp. Med. 203, 2413–2418 (2006).
Grech, A.P. et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 21, 629–642 (2004).
Annunziata, C.M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007).
Keats, J.J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131–144 (2007).
Bonizzi, G. et al. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23, 4202–4210 (2004).
Hunter, A.M., LaCasse, E.C. & Korneluk, R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12, 1543–1568 (2007).
Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669–681 (2007).
Vince, J.E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682–693 (2007).
Conte, D. et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol. Cell. Biol. 26, 699–708 (2006).
Conze, D.B. et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol. Cell. Biol. 25, 3348–3356 (2005).
Malinin, N.L., Boldin, M.P., Kovalenko, A.V. & Wallach, D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385, 540–544 (1997).
Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. & Goeddel, D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83, 1243–1252 (1995).
He, L., Grammer, A.C., Wu, X. & Lipsky, P.E. TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-κB activation. J. Biol. Chem. 279, 55855–55865 (2004).
Dadgostar, H. & Cheng, G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-κB activation but is dispensable for c-Jun N-terminal kinase signaling. J. Biol. Chem. 273, 24775–24780 (1998).
He, J.Q., Saha, S.K., Kang, J.R., Zarnegar, B. & Cheng, G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-κB pathway. J. Biol. Chem. 282, 3688–3694 (2007).
Saha, S.K. et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J. 25, 3257–3263 (2006).
Brown, K.D., Hostager, B.S. & Bishop, G.A. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J. Exp. Med. 193, 943–954 (2001).
Brown, K.D., Hostager, B.S. & Bishop, G.A. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277, 19433–19438 (2002).
Moore, C.R. & Bishop, G.A. Differential regulation of CD40-mediated TNF receptor-associated factor degradation in B lymphocytes. J. Immunol. 175, 3780–3789 (2005).
Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471–1474 (2004).
Ng, L.G. et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36, 1837–1846 (2006).
Zarnegar, B., Yamazaki, S., He, J.Q. & Cheng, G. Control of canonical NF-κB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. USA 105, 3503–3508 (2008).
Beg, A.A., Sha, W.C., Bronson, R.T. & Baltimore, D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9, 2736–2746 (1995).
Gardam, S., Sierro, F., Basten, A., Mackay, F. & Brink, R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28, 391–401 (2008).
Matsuzawa, A. et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321, 663–668 (2008).
Gaither, A. et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res. 67, 11493–11498 (2007).
Fischer, U., Janssen, K. & Schulze-Osthoff, K. Cutting-edge apoptosis-based therapeutics: a panacea for cancer? BioDrugs 21, 273–297 (2007).
Xu, Y., Cheng, G. & Baltimore, D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 5, 407–415 (1996).
Sha, W.C., Liou, H.C., Tuomanen, E.I. & Baltimore, D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80, 321–330 (1995).
Holcik, M., Lefebvre, C.A., Hicks, K. & Korneluk, R.G. Cloning and characterization of the rat homologues of the Inhibitor of Apoptosis protein 1, 2, and 3 genes. BMC Genomics 3, 5 (2002).
Scherle, P.A., Dorshkind, K. & Witte, O.N. Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc. Natl. Acad. Sci. USA 87, 1908–1912 (1990).
Acknowledgements
We thank X. Wang (University of Texas Southwestern Medical Center) for the SMAC mimetic compound, L. Zawel and Novartis Pharmaceuticals for LBW242, and Amgen for BAFF and for Map3k14−/− mice. Supported by the US National Institutes of Health (R01GM078607 and R01GM57559, G.C.) and the Canadian Institutes of Health Research and Howard Hughes Medical Institute (R.G.K.).
Author information
Authors and Affiliations
Contributions
B.J.Z. and Y.W. designed and performed all the experiments unless otherwise stated. D.J.M. and H.H.C. did the siRNA knock-down assay in Birc2−/− and Birc3−/− cells. P.W.D. examined lymphocyte lineages and gene expression in mice. J.H. generated reconstituted MEFs and BCR-Abl–transformed Traf3−/− B cells. T.S. generated chimeric constructs. X.Y. provided the cIAP constructs. W.-c.Y. provided Traf2−/− 3T3 cells. T.W.M. provided Birc2−/− MEF cells. R.G.K. provided the cIAP antibody and Birc3−/− cells and supervised the work of D.J.M. and H.H.C. G.C. supervised the work, and all authors contributed to discussions and to the preparation of the manuscript.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–9 and Supplementary Table 1 (PDF 446 kb)
Rights and permissions
About this article
Cite this article
Zarnegar, B., Wang, Y., Mahoney, D. et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 9, 1371–1378 (2008). https://doi.org/10.1038/ni.1676
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.1676